AG 24322

Drug Profile

AG 24322

Alternative Names: AG 024322; AG-24322

Latest Information Update: 12 Aug 2009

Price : $50

At a glance

  • Originator Agouron Pharmaceuticals
  • Class Antineoplastics; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
  • 05 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section
  • 20 Apr 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top